Locally Advanced Non-Small Cell Lung Cancer Clinical Trials

9 recruitingLast updated: June 17, 2026

There are 9 actively recruiting locally advanced non-small cell lung cancer clinical trials across 2 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Guangzhou, Guangdong, China, Bethesda, Maryland, United States, Chongqing, Chongqing Municipality, China. Updated daily from ClinicalTrials.gov.


Locally Advanced Non-Small Cell Lung Cancer Trials at a Glance

9 actively recruiting trials for locally advanced non-small cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Guangzhou, Bethesda, and Chongqing. Lead sponsors running locally advanced non-small cell lung cancer studies include Sun Yat-sen University, M.D. Anderson Cancer Center, and JIANYANG WANG.

Browse locally advanced non-small cell lung cancer trials by phase

Treatments under study

About Locally Advanced Non-Small Cell Lung Cancer Clinical Trials

Looking for clinical trials for Locally Advanced Non-Small Cell Lung Cancer? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Non-Small Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Non-Small Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Hepatocellular CarcinomaLocally Advanced MelanomaMetastatic Hepatocellular Carcinoma+7 more
National Cancer Institute (NCI)30 enrolled1 locationNCT06066138
Recruiting
Phase 2

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

Locally Advanced Non-Small Cell Lung CancerStage IIIb Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung Cancer
Yang Hong28 enrolled1 locationNCT07309952
Recruiting
Phase 1Phase 2

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer

Locally Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center40 enrolled1 locationNCT07224152
Recruiting
Not Applicable

RAPART in Locally Advanced Non-small Cell Lung Cancer Patients

Locally Advanced Non-Small Cell Lung Cancer
Capital Medical University911 enrolled1 locationNCT07164885
Recruiting
Phase 3

Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC

Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University311 enrolled3 locationsNCT07052669
Recruiting
Phase 3

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Neoadjuvant TherapyImmunotherapyLocally Advanced Non-Small Cell Lung Cancer+1 more
Sun Yat-sen University497 enrolled1 locationNCT06734702
Recruiting
Phase 2

Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

SafetyLocally Advanced Non-Small Cell Lung CancerThoracic Radiotherapy
JIANYANG WANG44 enrolled1 locationNCT07037680
Recruiting
Phase 2

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Non-small Cell Lung CancerAntineoplastic AgentsEGFR+5 more
Peng Zhang60 enrolled1 locationNCT06755684
Recruiting

Patient's Whole Process Follow-up Management(HOPE-1)

Metastatic NSCLCLocally Advanced Non-Small Cell Lung Cancer
Qianfoshan Hospital1,268 enrolled1 locationNCT05339568